Not Yet RecruitingNot Applicable

BaiXiaoAi AI Companion for Cancer Patient Follow-up

300 participantsStarted 2026-01-14

Plain-language summary

This is a prospective, single-center, exploratory study designed to evaluate the accuracy, user engagement, and user experience of the BaiXiaoAi Companion AI. Upon signing the informed consent form and enrollment, a dedicated "Doctor-Nurse-Patient-AI" WeChat group will be established for each participant. Within the group, the BaiXiaoAi AI will provide timely responses based on patient communications and proactively push information regarding disease management and patient education.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18 years or older; * Patients with a confirmed diagnosis of malignant neoplasms who are currently undergoing treatment or in follow-up, or their primary caregivers; * Able to read and communicate in Chinese and independently use WeChat; * Willing and able to provide informed consent. Exclusion Criteria: * Presence of severe psychiatric disorders (e.g., schizophrenia, bipolar disorder) or cognitive impairment (MMSE score \< 24); * Inability to use WeChat or communicate in Chinese; * Considered by the investigators to be unsuitable for participation due to psychological or physical conditions.

What they're measuring

Accuracy and safety of AI-assisted patient communication

Timeframe: Up to 12 months

Trial details

NCT IDNCT07396142

SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-11-30

Contact for this trial

Dandan Cui, MD

+86 0316-5916013 cuidan@cicams.ac.cn

View on ClinicalTrials.gov More Symptoms and Signs trials